Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Mlynarek

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Journal of Affective Disorders|March 22, 2023
Genetic predisposition to depression and inflammation impacts symptom burden and survival in patients with head and neck cancer: A longitudinal studyMelissa Henry, Raphaële Harvey, Lawrence M Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2024
Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized TrialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR TrialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
The Lancet. Oncology|August 17, 2019
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
JAMA Oncology|April 28, 2022
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical TrialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
BMC Cancer|February 16, 2020
Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trialAnthony C Nichols, Pencilla Lang, Eitan Prisman, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Journal of Affective Disorders|March 22, 2023
Genetic predisposition to depression and inflammation impacts symptom burden and survival in patients with head and neck cancer: A longitudinal studyMelissa Henry, Raphaële Harvey, Lawrence M Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2024
Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized TrialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2022
Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR TrialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
The Lancet. Oncology|August 17, 2019
Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trialAnthony C Nichols, Julie Theurer, Eitan Prisman, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: Primary analysis of the ORATOR2 randomized trialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
JAMA Oncology|April 28, 2022
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical TrialDavid A Palma, Eitan Prisman, Eric Berthelet, et al.
BMC Cancer|February 16, 2020
Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trialAnthony C Nichols, Pencilla Lang, Eitan Prisman, et al.
Pageof 8